Would you treat a patient with an early stage favorable breast cancer who has synchronous advanced (or metastatic) NSCLC?

Unfortunately, despite recent advances, the survival for locally advanced or metastatic NSCLC remains poor. As someone who treats both lung and breast, I would have a multi-disciplinary discussion with the teams regarding any added benefit of treating the early stage breast cancer. I think the factors to be considered will depend more heavily on the lung cancer rather than the breast cancer. For example, if patient has oligometastatic disease and can be rendered disease-free after aggressive che...